lotixparib

Lotixparib is an investigational **small-molecule, PARP-1 selective inhibitor** being developed as an anticancer therapy under the development code **DM5167**. Public sources identify it as a next-generation PARP inhibitor designed to preferentially inhibit **poly(ADP-ribose) polymerase 1** over PARP2, with the goal of maintaining antitumor activity while reducing the hematologic toxicity associated with earlier nonselective PARP inhibitors. It has entered **Phase 1** clinical testing in patients with **advanced solid tumors**, and preclinical reports and conference abstracts have described activity in homologous recombination-deficient tumor models, including triple-negative breast cancer.

Other names

lotixparib